nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—WEE1—central nervous system—Gilles de la Tourette syndrome	0.00387	0.00465	CbGeAlD
Bosutinib—DMPK—central nervous system—Gilles de la Tourette syndrome	0.00387	0.00465	CbGeAlD
Bosutinib—TLK1—brain—Gilles de la Tourette syndrome	0.00384	0.00462	CbGeAlD
Bosutinib—STK25—nervous system—Gilles de la Tourette syndrome	0.00383	0.00461	CbGeAlD
Bosutinib—ERBB4—midbrain—Gilles de la Tourette syndrome	0.00383	0.00461	CbGeAlD
Bosutinib—EPHA3—nervous system—Gilles de la Tourette syndrome	0.00381	0.00458	CbGeAlD
Bosutinib—PRKCQ—brain—Gilles de la Tourette syndrome	0.00379	0.00456	CbGeAlD
Bosutinib—SIK2—brain—Gilles de la Tourette syndrome	0.00373	0.00449	CbGeAlD
Bosutinib—STK33—brain—Gilles de la Tourette syndrome	0.00373	0.00449	CbGeAlD
Bosutinib—PLK2—nervous system—Gilles de la Tourette syndrome	0.00373	0.00449	CbGeAlD
Bosutinib—SIK3—nervous system—Gilles de la Tourette syndrome	0.0037	0.00446	CbGeAlD
Bosutinib—STK25—central nervous system—Gilles de la Tourette syndrome	0.00369	0.00444	CbGeAlD
Bosutinib—BMPR2—midbrain—Gilles de la Tourette syndrome	0.00367	0.00442	CbGeAlD
Bosutinib—EPHA3—central nervous system—Gilles de la Tourette syndrome	0.00366	0.00441	CbGeAlD
Bosutinib—PKMYT1—brain—Gilles de la Tourette syndrome	0.00364	0.00438	CbGeAlD
Bosutinib—PLK2—central nervous system—Gilles de la Tourette syndrome	0.00359	0.00432	CbGeAlD
Bosutinib—SIK3—central nervous system—Gilles de la Tourette syndrome	0.00356	0.00429	CbGeAlD
Bosutinib—STK4—nervous system—Gilles de la Tourette syndrome	0.00356	0.00429	CbGeAlD
Bosutinib—DSTYK—brain—Gilles de la Tourette syndrome	0.00355	0.00428	CbGeAlD
Bosutinib—CLK3—brain—Gilles de la Tourette syndrome	0.00355	0.00428	CbGeAlD
Bosutinib—MAP4K4—midbrain—Gilles de la Tourette syndrome	0.00353	0.00425	CbGeAlD
Bosutinib—CAMK1D—nervous system—Gilles de la Tourette syndrome	0.00352	0.00424	CbGeAlD
Bosutinib—HIPK4—brain—Gilles de la Tourette syndrome	0.00351	0.00423	CbGeAlD
Bosutinib—BCR—midbrain—Gilles de la Tourette syndrome	0.00351	0.00422	CbGeAlD
Bosutinib—MAP3K12—midbrain—Gilles de la Tourette syndrome	0.00348	0.00419	CbGeAlD
Bosutinib—STK24—nervous system—Gilles de la Tourette syndrome	0.00348	0.00419	CbGeAlD
Bosutinib—PHKG1—brain—Gilles de la Tourette syndrome	0.00347	0.00418	CbGeAlD
Bosutinib—EPHB2—brain—Gilles de la Tourette syndrome	0.00347	0.00418	CbGeAlD
Bosutinib—CASK—brain—Gilles de la Tourette syndrome	0.00347	0.00418	CbGeAlD
Bosutinib—EIF2AK1—brain—Gilles de la Tourette syndrome	0.00343	0.00413	CbGeAlD
Bosutinib—STK4—central nervous system—Gilles de la Tourette syndrome	0.00343	0.00413	CbGeAlD
Bosutinib—STK35—midbrain—Gilles de la Tourette syndrome	0.00341	0.00411	CbGeAlD
Bosutinib—SRMS—brain—Gilles de la Tourette syndrome	0.0034	0.00409	CbGeAlD
Bosutinib—CSK—midbrain—Gilles de la Tourette syndrome	0.00339	0.00408	CbGeAlD
Bosutinib—CAMK1D—central nervous system—Gilles de la Tourette syndrome	0.00339	0.00408	CbGeAlD
Bosutinib—CSNK1A1—midbrain—Gilles de la Tourette syndrome	0.00337	0.00405	CbGeAlD
Bosutinib—FER—nervous system—Gilles de la Tourette syndrome	0.00337	0.00405	CbGeAlD
Bosutinib—TYRO3—nervous system—Gilles de la Tourette syndrome	0.00337	0.00405	CbGeAlD
Bosutinib—EPHA5—nervous system—Gilles de la Tourette syndrome	0.00337	0.00405	CbGeAlD
Bosutinib—ALK—nervous system—Gilles de la Tourette syndrome	0.00337	0.00405	CbGeAlD
Bosutinib—STK24—central nervous system—Gilles de la Tourette syndrome	0.00335	0.00403	CbGeAlD
Bosutinib—LYN—nervous system—Gilles de la Tourette syndrome	0.00335	0.00403	CbGeAlD
Bosutinib—HCK—midbrain—Gilles de la Tourette syndrome	0.00335	0.00403	CbGeAlD
Bosutinib—CLK1—midbrain—Gilles de la Tourette syndrome	0.00335	0.00403	CbGeAlD
Bosutinib—EPHA8—brain—Gilles de la Tourette syndrome	0.00333	0.00401	CbGeAlD
Bosutinib—VRK2—brain—Gilles de la Tourette syndrome	0.00333	0.00401	CbGeAlD
Bosutinib—FES—brain—Gilles de la Tourette syndrome	0.00333	0.00401	CbGeAlD
Bosutinib—MAP3K19—nervous system—Gilles de la Tourette syndrome	0.0033	0.00397	CbGeAlD
Bosutinib—CAMK2G—midbrain—Gilles de la Tourette syndrome	0.00329	0.00395	CbGeAlD
Bosutinib—BMP2K—midbrain—Gilles de la Tourette syndrome	0.00329	0.00395	CbGeAlD
Bosutinib—TNIK—brain—Gilles de la Tourette syndrome	0.00326	0.00393	CbGeAlD
Bosutinib—SYK—brain—Gilles de la Tourette syndrome	0.00326	0.00393	CbGeAlD
Bosutinib—LRRK2—midbrain—Gilles de la Tourette syndrome	0.00326	0.00392	CbGeAlD
Bosutinib—EPHA5—central nervous system—Gilles de la Tourette syndrome	0.00324	0.0039	CbGeAlD
Bosutinib—FER—central nervous system—Gilles de la Tourette syndrome	0.00324	0.0039	CbGeAlD
Bosutinib—ALK—central nervous system—Gilles de la Tourette syndrome	0.00324	0.0039	CbGeAlD
Bosutinib—TYRO3—central nervous system—Gilles de la Tourette syndrome	0.00324	0.0039	CbGeAlD
Bosutinib—TNK2—nervous system—Gilles de la Tourette syndrome	0.00324	0.0039	CbGeAlD
Bosutinib—CDK2—brain—Gilles de la Tourette syndrome	0.00323	0.00389	CbGeAlD
Bosutinib—LYN—central nervous system—Gilles de la Tourette syndrome	0.00323	0.00388	CbGeAlD
Bosutinib—STK26—brain—Gilles de la Tourette syndrome	0.0032	0.00386	CbGeAlD
Bosutinib—MAP3K19—central nervous system—Gilles de la Tourette syndrome	0.00318	0.00382	CbGeAlD
Bosutinib—ERBB4—nervous system—Gilles de la Tourette syndrome	0.00315	0.00379	CbGeAlD
Bosutinib—CSNK1E—midbrain—Gilles de la Tourette syndrome	0.00312	0.00376	CbGeAlD
Bosutinib—TNK2—central nervous system—Gilles de la Tourette syndrome	0.00312	0.00375	CbGeAlD
Bosutinib—ROCK1—nervous system—Gilles de la Tourette syndrome	0.00311	0.00374	CbGeAlD
Bosutinib—CHEK2—brain—Gilles de la Tourette syndrome	0.00309	0.00372	CbGeAlD
Bosutinib—DMPK—brain—Gilles de la Tourette syndrome	0.00307	0.00369	CbGeAlD
Bosutinib—WEE1—brain—Gilles de la Tourette syndrome	0.00307	0.00369	CbGeAlD
Bosutinib—ERBB4—central nervous system—Gilles de la Tourette syndrome	0.00303	0.00365	CbGeAlD
Bosutinib—BMPR2—nervous system—Gilles de la Tourette syndrome	0.00302	0.00363	CbGeAlD
Bosutinib—ERBB3—midbrain—Gilles de la Tourette syndrome	0.00301	0.00363	CbGeAlD
Bosutinib—MAP2K2—midbrain—Gilles de la Tourette syndrome	0.003	0.00362	CbGeAlD
Bosutinib—ULK3—midbrain—Gilles de la Tourette syndrome	0.003	0.00362	CbGeAlD
Bosutinib—STK36—nervous system—Gilles de la Tourette syndrome	0.00299	0.0036	CbGeAlD
Bosutinib—EPHB3—nervous system—Gilles de la Tourette syndrome	0.00299	0.0036	CbGeAlD
Bosutinib—ROCK1—central nervous system—Gilles de la Tourette syndrome	0.00299	0.0036	CbGeAlD
Bosutinib—MERTK—nervous system—Gilles de la Tourette syndrome	0.00296	0.00356	CbGeAlD
Bosutinib—MAP3K7—midbrain—Gilles de la Tourette syndrome	0.00296	0.00356	CbGeAlD
Bosutinib—STK25—brain—Gilles de la Tourette syndrome	0.00293	0.00353	CbGeAlD
Bosutinib—PTK2—midbrain—Gilles de la Tourette syndrome	0.00292	0.00352	CbGeAlD
Bosutinib—TBK1—midbrain—Gilles de la Tourette syndrome	0.00292	0.00352	CbGeAlD
Bosutinib—EPHA3—brain—Gilles de la Tourette syndrome	0.00291	0.0035	CbGeAlD
Bosutinib—BMPR2—central nervous system—Gilles de la Tourette syndrome	0.00291	0.0035	CbGeAlD
Bosutinib—MAP4K4—nervous system—Gilles de la Tourette syndrome	0.00291	0.0035	CbGeAlD
Bosutinib—BCR—nervous system—Gilles de la Tourette syndrome	0.00288	0.00347	CbGeAlD
Bosutinib—STK36—central nervous system—Gilles de la Tourette syndrome	0.00288	0.00347	CbGeAlD
Bosutinib—EPHB3—central nervous system—Gilles de la Tourette syndrome	0.00288	0.00347	CbGeAlD
Bosutinib—IRAK1—midbrain—Gilles de la Tourette syndrome	0.00286	0.00345	CbGeAlD
Bosutinib—MAP3K12—nervous system—Gilles de la Tourette syndrome	0.00286	0.00345	CbGeAlD
Bosutinib—MERTK—central nervous system—Gilles de la Tourette syndrome	0.00285	0.00343	CbGeAlD
Bosutinib—PLK2—brain—Gilles de la Tourette syndrome	0.00285	0.00343	CbGeAlD
Bosutinib—SIK3—brain—Gilles de la Tourette syndrome	0.00283	0.00341	CbGeAlD
Bosutinib—RPS6KB1—midbrain—Gilles de la Tourette syndrome	0.00281	0.00338	CbGeAlD
Bosutinib—MAP2K1—nervous system—Gilles de la Tourette syndrome	0.00281	0.00338	CbGeAlD
Bosutinib—STK35—nervous system—Gilles de la Tourette syndrome	0.00281	0.00338	CbGeAlD
Bosutinib—MAP4K4—central nervous system—Gilles de la Tourette syndrome	0.0028	0.00337	CbGeAlD
Bosutinib—CSK—nervous system—Gilles de la Tourette syndrome	0.00279	0.00336	CbGeAlD
Bosutinib—AXL—midbrain—Gilles de la Tourette syndrome	0.00278	0.00335	CbGeAlD
Bosutinib—BCR—central nervous system—Gilles de la Tourette syndrome	0.00278	0.00334	CbGeAlD
Bosutinib—CSNK1A1—nervous system—Gilles de la Tourette syndrome	0.00277	0.00333	CbGeAlD
Bosutinib—MAP3K12—central nervous system—Gilles de la Tourette syndrome	0.00276	0.00332	CbGeAlD
Bosutinib—HCK—nervous system—Gilles de la Tourette syndrome	0.00275	0.00331	CbGeAlD
Bosutinib—CLK1—nervous system—Gilles de la Tourette syndrome	0.00275	0.00331	CbGeAlD
Bosutinib—STK4—brain—Gilles de la Tourette syndrome	0.00272	0.00328	CbGeAlD
Bosutinib—MAP2K1—central nervous system—Gilles de la Tourette syndrome	0.0027	0.00325	CbGeAlD
Bosutinib—STK35—central nervous system—Gilles de la Tourette syndrome	0.0027	0.00325	CbGeAlD
Bosutinib—BMP2K—nervous system—Gilles de la Tourette syndrome	0.0027	0.00325	CbGeAlD
Bosutinib—CAMK2G—nervous system—Gilles de la Tourette syndrome	0.0027	0.00325	CbGeAlD
Bosutinib—CAMK1D—brain—Gilles de la Tourette syndrome	0.00269	0.00324	CbGeAlD
Bosutinib—CSK—central nervous system—Gilles de la Tourette syndrome	0.00268	0.00323	CbGeAlD
Bosutinib—SLK—midbrain—Gilles de la Tourette syndrome	0.00268	0.00322	CbGeAlD
Bosutinib—LRRK2—nervous system—Gilles de la Tourette syndrome	0.00268	0.00322	CbGeAlD
Bosutinib—CSNK1A1—central nervous system—Gilles de la Tourette syndrome	0.00267	0.00321	CbGeAlD
Bosutinib—STK24—brain—Gilles de la Tourette syndrome	0.00266	0.0032	CbGeAlD
Bosutinib—EPHB4—midbrain—Gilles de la Tourette syndrome	0.00266	0.0032	CbGeAlD
Bosutinib—HCK—central nervous system—Gilles de la Tourette syndrome	0.00265	0.00319	CbGeAlD
Bosutinib—CLK1—central nervous system—Gilles de la Tourette syndrome	0.00265	0.00319	CbGeAlD
Bosutinib—PTK2B—nervous system—Gilles de la Tourette syndrome	0.00261	0.00314	CbGeAlD
Bosutinib—FYN—midbrain—Gilles de la Tourette syndrome	0.0026	0.00313	CbGeAlD
Bosutinib—CAMK2G—central nervous system—Gilles de la Tourette syndrome	0.0026	0.00313	CbGeAlD
Bosutinib—BMP2K—central nervous system—Gilles de la Tourette syndrome	0.0026	0.00313	CbGeAlD
Bosutinib—LRRK2—central nervous system—Gilles de la Tourette syndrome	0.00258	0.0031	CbGeAlD
Bosutinib—FER—brain—Gilles de la Tourette syndrome	0.00257	0.0031	CbGeAlD
Bosutinib—TYRO3—brain—Gilles de la Tourette syndrome	0.00257	0.0031	CbGeAlD
Bosutinib—ALK—brain—Gilles de la Tourette syndrome	0.00257	0.0031	CbGeAlD
Bosutinib—EPHA5—brain—Gilles de la Tourette syndrome	0.00257	0.0031	CbGeAlD
Bosutinib—CSNK1E—nervous system—Gilles de la Tourette syndrome	0.00257	0.00309	CbGeAlD
Bosutinib—LYN—brain—Gilles de la Tourette syndrome	0.00256	0.00308	CbGeAlD
Bosutinib—MAP3K3—midbrain—Gilles de la Tourette syndrome	0.00254	0.00306	CbGeAlD
Bosutinib—MAP4K5—midbrain—Gilles de la Tourette syndrome	0.00254	0.00306	CbGeAlD
Bosutinib—SIK1—nervous system—Gilles de la Tourette syndrome	0.00253	0.00304	CbGeAlD
Bosutinib—IRAK4—nervous system—Gilles de la Tourette syndrome	0.00253	0.00304	CbGeAlD
Bosutinib—MAP4K1—brain—Gilles de la Tourette syndrome	0.00252	0.00304	CbGeAlD
Bosutinib—MAP3K19—brain—Gilles de la Tourette syndrome	0.00252	0.00304	CbGeAlD
Bosutinib—PTK2B—central nervous system—Gilles de la Tourette syndrome	0.00251	0.00302	CbGeAlD
Bosutinib—BTK—brain—Gilles de la Tourette syndrome	0.00251	0.00302	CbGeAlD
Bosutinib—EPHA4—nervous system—Gilles de la Tourette syndrome	0.0025	0.00301	CbGeAlD
Bosutinib—ERBB3—nervous system—Gilles de la Tourette syndrome	0.00248	0.00298	CbGeAlD
Bosutinib—TNK2—brain—Gilles de la Tourette syndrome	0.00247	0.00298	CbGeAlD
Bosutinib—CSNK1E—central nervous system—Gilles de la Tourette syndrome	0.00247	0.00297	CbGeAlD
Bosutinib—ULK3—nervous system—Gilles de la Tourette syndrome	0.00247	0.00297	CbGeAlD
Bosutinib—MAP2K2—nervous system—Gilles de la Tourette syndrome	0.00247	0.00297	CbGeAlD
Bosutinib—MAP3K2—nervous system—Gilles de la Tourette syndrome	0.00245	0.00295	CbGeAlD
Bosutinib—MAP4K2—brain—Gilles de la Tourette syndrome	0.00244	0.00294	CbGeAlD
Bosutinib—SIK1—central nervous system—Gilles de la Tourette syndrome	0.00243	0.00293	CbGeAlD
Bosutinib—IRAK4—central nervous system—Gilles de la Tourette syndrome	0.00243	0.00293	CbGeAlD
Bosutinib—EPHA4—central nervous system—Gilles de la Tourette syndrome	0.00241	0.0029	CbGeAlD
Bosutinib—ERBB4—brain—Gilles de la Tourette syndrome	0.00241	0.0029	CbGeAlD
Bosutinib—STK3—brain—Gilles de la Tourette syndrome	0.00241	0.0029	CbGeAlD
Bosutinib—PTK2—nervous system—Gilles de la Tourette syndrome	0.0024	0.00289	CbGeAlD
Bosutinib—TBK1—nervous system—Gilles de la Tourette syndrome	0.0024	0.00289	CbGeAlD
Bosutinib—ERBB3—central nervous system—Gilles de la Tourette syndrome	0.00238	0.00287	CbGeAlD
Bosutinib—MAP2K2—central nervous system—Gilles de la Tourette syndrome	0.00238	0.00286	CbGeAlD
Bosutinib—ULK3—central nervous system—Gilles de la Tourette syndrome	0.00238	0.00286	CbGeAlD
Bosutinib—ROCK1—brain—Gilles de la Tourette syndrome	0.00237	0.00286	CbGeAlD
Bosutinib—MAP3K2—central nervous system—Gilles de la Tourette syndrome	0.00236	0.00284	CbGeAlD
Bosutinib—YES1—midbrain—Gilles de la Tourette syndrome	0.00235	0.00283	CbGeAlD
Bosutinib—TAOK3—midbrain—Gilles de la Tourette syndrome	0.00232	0.00279	CbGeAlD
Bosutinib—PTK2—central nervous system—Gilles de la Tourette syndrome	0.00231	0.00278	CbGeAlD
Bosutinib—TBK1—central nervous system—Gilles de la Tourette syndrome	0.00231	0.00278	CbGeAlD
Bosutinib—RPS6KB1—nervous system—Gilles de la Tourette syndrome	0.00231	0.00278	CbGeAlD
Bosutinib—BMPR2—brain—Gilles de la Tourette syndrome	0.00231	0.00278	CbGeAlD
Bosutinib—FGR—nervous system—Gilles de la Tourette syndrome	0.0023	0.00276	CbGeAlD
Bosutinib—STK36—brain—Gilles de la Tourette syndrome	0.00229	0.00275	CbGeAlD
Bosutinib—EPHB3—brain—Gilles de la Tourette syndrome	0.00229	0.00275	CbGeAlD
Bosutinib—AXL—nervous system—Gilles de la Tourette syndrome	0.00229	0.00275	CbGeAlD
Bosutinib—MERTK—brain—Gilles de la Tourette syndrome	0.00226	0.00272	CbGeAlD
Bosutinib—RPS6KB1—central nervous system—Gilles de la Tourette syndrome	0.00222	0.00268	CbGeAlD
Bosutinib—MAP4K4—brain—Gilles de la Tourette syndrome	0.00222	0.00267	CbGeAlD
Bosutinib—FGR—central nervous system—Gilles de la Tourette syndrome	0.00221	0.00266	CbGeAlD
Bosutinib—NUAK2—brain—Gilles de la Tourette syndrome	0.0022	0.00265	CbGeAlD
Bosutinib—BCR—brain—Gilles de la Tourette syndrome	0.0022	0.00265	CbGeAlD
Bosutinib—AXL—central nervous system—Gilles de la Tourette syndrome	0.0022	0.00265	CbGeAlD
Bosutinib—MAP3K12—brain—Gilles de la Tourette syndrome	0.00219	0.00264	CbGeAlD
Bosutinib—MAP2K1—brain—Gilles de la Tourette syndrome	0.00214	0.00258	CbGeAlD
Bosutinib—STK35—brain—Gilles de la Tourette syndrome	0.00214	0.00258	CbGeAlD
Bosutinib—EPHA2—nervous system—Gilles de la Tourette syndrome	0.00214	0.00258	CbGeAlD
Bosutinib—FYN—nervous system—Gilles de la Tourette syndrome	0.00214	0.00258	CbGeAlD
Bosutinib—CSK—brain—Gilles de la Tourette syndrome	0.00213	0.00256	CbGeAlD
Bosutinib—CSNK1A1—brain—Gilles de la Tourette syndrome	0.00212	0.00255	CbGeAlD
Bosutinib—CLK1—brain—Gilles de la Tourette syndrome	0.0021	0.00253	CbGeAlD
Bosutinib—HCK—brain—Gilles de la Tourette syndrome	0.0021	0.00253	CbGeAlD
Bosutinib—MAP4K5—nervous system—Gilles de la Tourette syndrome	0.00209	0.00252	CbGeAlD
Bosutinib—MAP3K3—nervous system—Gilles de la Tourette syndrome	0.00209	0.00252	CbGeAlD
Bosutinib—ABL2—brain—Gilles de la Tourette syndrome	0.00209	0.00252	CbGeAlD
Bosutinib—MAP2K5—midbrain—Gilles de la Tourette syndrome	0.00208	0.0025	CbGeAlD
Bosutinib—EPHA2—central nervous system—Gilles de la Tourette syndrome	0.00206	0.00249	CbGeAlD
Bosutinib—CAMK2G—brain—Gilles de la Tourette syndrome	0.00206	0.00248	CbGeAlD
Bosutinib—BMP2K—brain—Gilles de la Tourette syndrome	0.00206	0.00248	CbGeAlD
Bosutinib—FYN—central nervous system—Gilles de la Tourette syndrome	0.00206	0.00248	CbGeAlD
Bosutinib—LRRK2—brain—Gilles de la Tourette syndrome	0.00205	0.00246	CbGeAlD
Bosutinib—EGFR—brain—Gilles de la Tourette syndrome	0.00204	0.00246	CbGeAlD
Bosutinib—CSF1R—midbrain—Gilles de la Tourette syndrome	0.00203	0.00244	CbGeAlD
Bosutinib—MAP3K3—central nervous system—Gilles de la Tourette syndrome	0.00201	0.00242	CbGeAlD
Bosutinib—MAP4K5—central nervous system—Gilles de la Tourette syndrome	0.00201	0.00242	CbGeAlD
Bosutinib—PTK2B—brain—Gilles de la Tourette syndrome	0.00199	0.0024	CbGeAlD
Bosutinib—CSNK1E—brain—Gilles de la Tourette syndrome	0.00196	0.00236	CbGeAlD
Bosutinib—YES1—nervous system—Gilles de la Tourette syndrome	0.00193	0.00233	CbGeAlD
Bosutinib—SIK1—brain—Gilles de la Tourette syndrome	0.00193	0.00232	CbGeAlD
Bosutinib—IRAK4—brain—Gilles de la Tourette syndrome	0.00193	0.00232	CbGeAlD
Bosutinib—STK10—nervous system—Gilles de la Tourette syndrome	0.00191	0.0023	CbGeAlD
Bosutinib—EPHA4—brain—Gilles de la Tourette syndrome	0.00191	0.0023	CbGeAlD
Bosutinib—TAOK3—nervous system—Gilles de la Tourette syndrome	0.00191	0.0023	CbGeAlD
Bosutinib—ERBB3—brain—Gilles de la Tourette syndrome	0.00189	0.00228	CbGeAlD
Bosutinib—MAP2K2—brain—Gilles de la Tourette syndrome	0.00189	0.00227	CbGeAlD
Bosutinib—ULK3—brain—Gilles de la Tourette syndrome	0.00189	0.00227	CbGeAlD
Bosutinib—MAP3K2—brain—Gilles de la Tourette syndrome	0.00187	0.00226	CbGeAlD
Bosutinib—YES1—central nervous system—Gilles de la Tourette syndrome	0.00186	0.00224	CbGeAlD
Bosutinib—SRC—nervous system—Gilles de la Tourette syndrome	0.00186	0.00224	CbGeAlD
Bosutinib—MAP3K7—brain—Gilles de la Tourette syndrome	0.00186	0.00224	CbGeAlD
Bosutinib—STK10—central nervous system—Gilles de la Tourette syndrome	0.00184	0.00222	CbGeAlD
Bosutinib—TAOK3—central nervous system—Gilles de la Tourette syndrome	0.00184	0.00221	CbGeAlD
Bosutinib—PTK2—brain—Gilles de la Tourette syndrome	0.00184	0.00221	CbGeAlD
Bosutinib—TBK1—brain—Gilles de la Tourette syndrome	0.00184	0.00221	CbGeAlD
Bosutinib—PDGFRB—midbrain—Gilles de la Tourette syndrome	0.0018	0.00217	CbGeAlD
Bosutinib—IRAK1—brain—Gilles de la Tourette syndrome	0.0018	0.00217	CbGeAlD
Bosutinib—SRC—central nervous system—Gilles de la Tourette syndrome	0.00179	0.00215	CbGeAlD
Bosutinib—RPS6KB1—brain—Gilles de la Tourette syndrome	0.00177	0.00213	CbGeAlD
Bosutinib—FGR—brain—Gilles de la Tourette syndrome	0.00176	0.00211	CbGeAlD
Bosutinib—AXL—brain—Gilles de la Tourette syndrome	0.00175	0.0021	CbGeAlD
Bosutinib—MAP2K5—nervous system—Gilles de la Tourette syndrome	0.00171	0.00206	CbGeAlD
Bosutinib—SLK—brain—Gilles de la Tourette syndrome	0.00168	0.00203	CbGeAlD
Bosutinib—EPHB4—brain—Gilles de la Tourette syndrome	0.00167	0.00201	CbGeAlD
Bosutinib—CSF1R—nervous system—Gilles de la Tourette syndrome	0.00167	0.00201	CbGeAlD
Bosutinib—MAP2K5—central nervous system—Gilles de la Tourette syndrome	0.00165	0.00198	CbGeAlD
Bosutinib—EPHA2—brain—Gilles de la Tourette syndrome	0.00164	0.00197	CbGeAlD
Bosutinib—FYN—brain—Gilles de la Tourette syndrome	0.00164	0.00197	CbGeAlD
Bosutinib—CSF1R—central nervous system—Gilles de la Tourette syndrome	0.00161	0.00193	CbGeAlD
Bosutinib—ABL1—midbrain—Gilles de la Tourette syndrome	0.0016	0.00193	CbGeAlD
Bosutinib—MAP4K5—brain—Gilles de la Tourette syndrome	0.0016	0.00192	CbGeAlD
Bosutinib—MAP3K3—brain—Gilles de la Tourette syndrome	0.0016	0.00192	CbGeAlD
Bosutinib—PDGFRB—nervous system—Gilles de la Tourette syndrome	0.00148	0.00178	CbGeAlD
Bosutinib—YES1—brain—Gilles de la Tourette syndrome	0.00148	0.00178	CbGeAlD
Bosutinib—STK10—brain—Gilles de la Tourette syndrome	0.00146	0.00176	CbGeAlD
Bosutinib—TAOK3—brain—Gilles de la Tourette syndrome	0.00146	0.00175	CbGeAlD
Bosutinib—PDGFRB—central nervous system—Gilles de la Tourette syndrome	0.00142	0.00171	CbGeAlD
Bosutinib—SRC—brain—Gilles de la Tourette syndrome	0.00142	0.00171	CbGeAlD
Bosutinib—ABL1—nervous system—Gilles de la Tourette syndrome	0.00132	0.00159	CbGeAlD
Bosutinib—MAP2K5—brain—Gilles de la Tourette syndrome	0.00131	0.00157	CbGeAlD
Bosutinib—CSF1R—brain—Gilles de la Tourette syndrome	0.00128	0.00154	CbGeAlD
Bosutinib—ABL1—central nervous system—Gilles de la Tourette syndrome	0.00127	0.00153	CbGeAlD
Bosutinib—PDGFRB—brain—Gilles de la Tourette syndrome	0.00113	0.00136	CbGeAlD
Bosutinib—ABL1—brain—Gilles de la Tourette syndrome	0.00101	0.00121	CbGeAlD
Bosutinib—PDGFRB—Signaling events mediated by TCPTP—MET—Gilles de la Tourette syndrome	0.000957	0.00566	CbGpPWpGaD
Bosutinib—CSNK1E—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.000915	0.00541	CbGpPWpGaD
Bosutinib—CAMK2G—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.000889	0.00526	CbGpPWpGaD
Bosutinib—CSNK1E—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.000888	0.00525	CbGpPWpGaD
Bosutinib—EGFR—Arf6 signaling events—MET—Gilles de la Tourette syndrome	0.000887	0.00524	CbGpPWpGaD
Bosutinib—MAP4K1—TGF-beta Signaling Pathway—MET—Gilles de la Tourette syndrome	0.000864	0.00511	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways in Glioblastoma—MET—Gilles de la Tourette syndrome	0.000836	0.00494	CbGpPWpGaD
Bosutinib—CSNK1E—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.000827	0.00489	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways in Glioblastoma—MET—Gilles de la Tourette syndrome	0.000806	0.00476	CbGpPWpGaD
Bosutinib—ABL1—Posttranslational regulation of adherens junction stability and dissassembly—MET—Gilles de la Tourette syndrome	0.000806	0.00476	CbGpPWpGaD
Bosutinib—FYN—Posttranslational regulation of adherens junction stability and dissassembly—MET—Gilles de la Tourette syndrome	0.000797	0.00471	CbGpPWpGaD
Bosutinib—EGFR—Signaling events mediated by TCPTP—MET—Gilles de la Tourette syndrome	0.000797	0.00471	CbGpPWpGaD
Bosutinib—SRC—Signaling of Hepatocyte Growth Factor Receptor—MET—Gilles de la Tourette syndrome	0.000774	0.00458	CbGpPWpGaD
Bosutinib—EGFR—Stabilization and expansion of the E-cadherin adherens junction—MET—Gilles de la Tourette syndrome	0.000766	0.00453	CbGpPWpGaD
Bosutinib—PRKCQ—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00076	0.00449	CbGpPWpGaD
Bosutinib—SRC—Arf6 signaling events—MET—Gilles de la Tourette syndrome	0.000757	0.00447	CbGpPWpGaD
Bosutinib—EPHA2—Direct p53 effectors—MET—Gilles de la Tourette syndrome	0.000754	0.00446	CbGpPWpGaD
Bosutinib—PTK2—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—MET—Gilles de la Tourette syndrome	0.000732	0.00433	CbGpPWpGaD
Bosutinib—EGFR—a6b1 and a6b4 Integrin signaling—MET—Gilles de la Tourette syndrome	0.000725	0.00429	CbGpPWpGaD
Bosutinib—EGFR—Posttranslational regulation of adherens junction stability and dissassembly—MET—Gilles de la Tourette syndrome	0.000689	0.00407	CbGpPWpGaD
Bosutinib—CAMK2G—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.000682	0.00403	CbGpPWpGaD
Bosutinib—SRC—Signaling events mediated by TCPTP—MET—Gilles de la Tourette syndrome	0.00068	0.00402	CbGpPWpGaD
Bosutinib—PRKCQ—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00068	0.00402	CbGpPWpGaD
Bosutinib—ABL1—Regulation of retinoblastoma protein—MET—Gilles de la Tourette syndrome	0.000625	0.00369	CbGpPWpGaD
Bosutinib—FYN—Semaphorin interactions—MET—Gilles de la Tourette syndrome	0.000611	0.00361	CbGpPWpGaD
Bosutinib—ROCK1—TGF-beta Signaling Pathway—MET—Gilles de la Tourette syndrome	0.000593	0.00351	CbGpPWpGaD
Bosutinib—SRC—Posttranslational regulation of adherens junction stability and dissassembly—MET—Gilles de la Tourette syndrome	0.000588	0.00347	CbGpPWpGaD
Bosutinib—CYP3A4—nervous system—Gilles de la Tourette syndrome	0.000579	0.000697	CbGeAlD
Bosutinib—MAP2K2—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—MET—Gilles de la Tourette syndrome	0.000563	0.00333	CbGpPWpGaD
Bosutinib—CYP3A4—central nervous system—Gilles de la Tourette syndrome	0.000558	0.000671	CbGeAlD
Bosutinib—EPHB3—Axon guidance—MET—Gilles de la Tourette syndrome	0.000556	0.00329	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways in Glioblastoma—MET—Gilles de la Tourette syndrome	0.000552	0.00326	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways in Glioblastoma—MET—Gilles de la Tourette syndrome	0.000539	0.00318	CbGpPWpGaD
Bosutinib—SRC—FGF signaling pathway—MET—Gilles de la Tourette syndrome	0.000535	0.00316	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—MET—Gilles de la Tourette syndrome	0.000527	0.00311	CbGpPWpGaD
Bosutinib—FES—Axon guidance—MET—Gilles de la Tourette syndrome	0.000523	0.00309	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways in Glioblastoma—MET—Gilles de la Tourette syndrome	0.000517	0.00305	CbGpPWpGaD
Bosutinib—ABCB1—midbrain—Gilles de la Tourette syndrome	0.000499	0.000601	CbGeAlD
Bosutinib—HCK—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000496	0.00293	CbGpPWpGaD
Bosutinib—EPHA5—Axon guidance—MET—Gilles de la Tourette syndrome	0.000496	0.00293	CbGpPWpGaD
Bosutinib—EPHA3—Axon guidance—MET—Gilles de la Tourette syndrome	0.000496	0.00293	CbGpPWpGaD
Bosutinib—ABL2—Axon guidance—MET—Gilles de la Tourette syndrome	0.000496	0.00293	CbGpPWpGaD
Bosutinib—PTK2—TGF-beta Signaling Pathway—MET—Gilles de la Tourette syndrome	0.00049	0.0029	CbGpPWpGaD
Bosutinib—EPHA8—Axon guidance—MET—Gilles de la Tourette syndrome	0.000478	0.00283	CbGpPWpGaD
Bosutinib—EPHB4—Axon guidance—MET—Gilles de la Tourette syndrome	0.000473	0.00279	CbGpPWpGaD
Bosutinib—EPHA4—Axon guidance—MET—Gilles de la Tourette syndrome	0.000473	0.00279	CbGpPWpGaD
Bosutinib—EPHB2—Axon guidance—MET—Gilles de la Tourette syndrome	0.000458	0.00271	CbGpPWpGaD
Bosutinib—BLK—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000449	0.00265	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways in Glioblastoma—MET—Gilles de la Tourette syndrome	0.000449	0.00265	CbGpPWpGaD
Bosutinib—FGR—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000448	0.00265	CbGpPWpGaD
Bosutinib—ROCK1—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000443	0.00262	CbGpPWpGaD
Bosutinib—PRKCQ—Axon guidance—MET—Gilles de la Tourette syndrome	0.000436	0.00258	CbGpPWpGaD
Bosutinib—MAP3K7—TGF-beta Signaling Pathway—MET—Gilles de la Tourette syndrome	0.000432	0.00255	CbGpPWpGaD
Bosutinib—MAP2K5—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000427	0.00252	CbGpPWpGaD
Bosutinib—ABCB1—nervous system—Gilles de la Tourette syndrome	0.00041	0.000494	CbGeAlD
Bosutinib—STK4—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000407	0.0024	CbGpPWpGaD
Bosutinib—EPHB3—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000397	0.00234	CbGpPWpGaD
Bosutinib—STK4—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000395	0.00233	CbGpPWpGaD
Bosutinib—ABCB1—central nervous system—Gilles de la Tourette syndrome	0.000395	0.000475	CbGeAlD
Bosutinib—SRC—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—MET—Gilles de la Tourette syndrome	0.000391	0.00231	CbGpPWpGaD
Bosutinib—EPHA2—Axon guidance—MET—Gilles de la Tourette syndrome	0.000385	0.00228	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways in Glioblastoma—MET—Gilles de la Tourette syndrome	0.000383	0.00226	CbGpPWpGaD
Bosutinib—MAP2K2—TGF-beta Signaling Pathway—MET—Gilles de la Tourette syndrome	0.000377	0.00223	CbGpPWpGaD
Bosutinib—FES—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000373	0.0022	CbGpPWpGaD
Bosutinib—STK4—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000368	0.00217	CbGpPWpGaD
Bosutinib—PTK2—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000366	0.00217	CbGpPWpGaD
Bosutinib—EPHA3—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000354	0.00209	CbGpPWpGaD
Bosutinib—EPHA5—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000354	0.00209	CbGpPWpGaD
Bosutinib—ABL2—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000354	0.00209	CbGpPWpGaD
Bosutinib—MAP2K1—TGF-beta Signaling Pathway—MET—Gilles de la Tourette syndrome	0.000353	0.00209	CbGpPWpGaD
Bosutinib—STK3—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000346	0.00204	CbGpPWpGaD
Bosutinib—PRKCQ—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000342	0.00202	CbGpPWpGaD
Bosutinib—EPHA8—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000341	0.00202	CbGpPWpGaD
Bosutinib—EPHA4—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000337	0.00199	CbGpPWpGaD
Bosutinib—EPHB4—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000337	0.00199	CbGpPWpGaD
Bosutinib—STK3—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000336	0.00199	CbGpPWpGaD
Bosutinib—PRKCQ—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000332	0.00196	CbGpPWpGaD
Bosutinib—EPHB2—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000327	0.00193	CbGpPWpGaD
Bosutinib—ABCB1—brain—Gilles de la Tourette syndrome	0.000314	0.000377	CbGeAlD
Bosutinib—STK3—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000313	0.00185	CbGpPWpGaD
Bosutinib—PRKCQ—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000311	0.00184	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00031	0.00183	CbGpPWpGaD
Bosutinib—PRKCQ—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000309	0.00183	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000301	0.00178	CbGpPWpGaD
Bosutinib—EGFR—Direct p53 effectors—MET—Gilles de la Tourette syndrome	0.000293	0.00173	CbGpPWpGaD
Bosutinib—FER—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00029	0.00171	CbGpPWpGaD
Bosutinib—ROCK1—Axon guidance—MET—Gilles de la Tourette syndrome	0.000289	0.00171	CbGpPWpGaD
Bosutinib—MAP2K2—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.000287	0.00169	CbGpPWpGaD
Bosutinib—MAP2K2—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000282	0.00167	CbGpPWpGaD
Bosutinib—FER—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000281	0.00166	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000281	0.00166	CbGpPWpGaD
Bosutinib—PDGFRB—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000275	0.00163	CbGpPWpGaD
Bosutinib—EPHA2—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000275	0.00163	CbGpPWpGaD
Bosutinib—AXL—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000275	0.00162	CbGpPWpGaD
Bosutinib—MAP2K1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.000268	0.00158	CbGpPWpGaD
Bosutinib—AXL—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000267	0.00158	CbGpPWpGaD
Bosutinib—FYN—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000265	0.00157	CbGpPWpGaD
Bosutinib—MAP2K1—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000264	0.00156	CbGpPWpGaD
Bosutinib—BMPR2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000262	0.00155	CbGpPWpGaD
Bosutinib—FER—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000262	0.00155	CbGpPWpGaD
Bosutinib—SRC—TGF-beta Signaling Pathway—MET—Gilles de la Tourette syndrome	0.000262	0.00155	CbGpPWpGaD
Bosutinib—STK4—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000258	0.00152	CbGpPWpGaD
Bosutinib—BMPR2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000255	0.0015	CbGpPWpGaD
Bosutinib—BCR—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000251	0.00149	CbGpPWpGaD
Bosutinib—AXL—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000249	0.00147	CbGpPWpGaD
Bosutinib—BCR—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000244	0.00144	CbGpPWpGaD
Bosutinib—PTK2—Axon guidance—MET—Gilles de la Tourette syndrome	0.000239	0.00141	CbGpPWpGaD
Bosutinib—BMPR2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000237	0.0014	CbGpPWpGaD
Bosutinib—YES1—Axon guidance—MET—Gilles de la Tourette syndrome	0.000236	0.00139	CbGpPWpGaD
Bosutinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.000233	0.00138	CbGpPWpGaD
Bosutinib—EGFR—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000229	0.00135	CbGpPWpGaD
Bosutinib—BCR—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000227	0.00134	CbGpPWpGaD
Bosutinib—ROCK1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000227	0.00134	CbGpPWpGaD
Bosutinib—ROCK1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00022	0.0013	CbGpPWpGaD
Bosutinib—FES—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00022	0.0013	CbGpPWpGaD
Bosutinib—STK3—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000219	0.0013	CbGpPWpGaD
Bosutinib—PRKCQ—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000217	0.00128	CbGpPWpGaD
Bosutinib—FES—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000213	0.00126	CbGpPWpGaD
Bosutinib—ROCK1—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000206	0.00122	CbGpPWpGaD
Bosutinib—ROCK1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000206	0.00122	CbGpPWpGaD
Bosutinib—ROCK1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000205	0.00121	CbGpPWpGaD
Bosutinib—ROCK1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.0002	0.00118	CbGpPWpGaD
Bosutinib—FES—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000199	0.00117	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000197	0.00116	CbGpPWpGaD
Bosutinib—SRC—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000195	0.00116	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000187	0.0011	CbGpPWpGaD
Bosutinib—ROCK1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000186	0.0011	CbGpPWpGaD
Bosutinib—MAP2K2—Axon guidance—MET—Gilles de la Tourette syndrome	0.000184	0.00109	CbGpPWpGaD
Bosutinib—FER—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000184	0.00109	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000183	0.00108	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000183	0.00108	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000181	0.00107	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000178	0.00105	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000178	0.00105	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000177	0.00105	CbGpPWpGaD
Bosutinib—LYN—Axon guidance—MET—Gilles de la Tourette syndrome	0.000176	0.00104	CbGpPWpGaD
Bosutinib—ABL1—Axon guidance—MET—Gilles de la Tourette syndrome	0.000175	0.00103	CbGpPWpGaD
Bosutinib—AXL—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000174	0.00103	CbGpPWpGaD
Bosutinib—FYN—Axon guidance—MET—Gilles de la Tourette syndrome	0.000173	0.00102	CbGpPWpGaD
Bosutinib—MAP2K1—Axon guidance—MET—Gilles de la Tourette syndrome	0.000172	0.00102	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000172	0.00102	CbGpPWpGaD
Bosutinib—PTK2—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000171	0.00101	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000169	0.000999	CbGpPWpGaD
Bosutinib—YES1—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000168	0.000994	CbGpPWpGaD
Bosutinib—BMPR2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000166	0.000982	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000166	0.00098	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000166	0.00098	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00016	0.000947	CbGpPWpGaD
Bosutinib—BCR—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000159	0.000941	CbGpPWpGaD
Bosutinib—EGFR—Axon guidance—MET—Gilles de la Tourette syndrome	0.00015	0.000884	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000148	0.000876	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000144	0.00085	CbGpPWpGaD
Bosutinib—ROCK1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000144	0.000848	CbGpPWpGaD
Bosutinib—FES—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000139	0.000823	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000134	0.000792	CbGpPWpGaD
Bosutinib—MAP2K2—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000131	0.000776	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000131	0.000774	CbGpPWpGaD
Bosutinib—ROCK1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00013	0.00077	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000128	0.000757	CbGpPWpGaD
Bosutinib—SRC—Axon guidance—MET—Gilles de la Tourette syndrome	0.000128	0.000754	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000127	0.000751	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000126	0.000746	CbGpPWpGaD
Bosutinib—LYN—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000125	0.000741	CbGpPWpGaD
Bosutinib—ABL1—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000125	0.000738	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000124	0.000735	CbGpPWpGaD
Bosutinib—FYN—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000123	0.00073	CbGpPWpGaD
Bosutinib—MAP2K1—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000123	0.000726	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000123	0.000724	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000122	0.000724	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000122	0.000718	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000119	0.000703	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000118	0.0007	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000118	0.000699	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000118	0.000697	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000117	0.000692	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000117	0.000692	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000116	0.000686	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000116	0.000686	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000116	0.000684	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000114	0.000675	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000114	0.000672	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000114	0.000672	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000113	0.000667	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000112	0.000663	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000111	0.000655	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00011	0.00065	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00011	0.000648	CbGpPWpGaD
Bosutinib—EGFR—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000107	0.00063	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000106	0.000629	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000106	0.000626	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000106	0.000626	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000103	0.00061	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000102	0.000603	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.0001	0.000594	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—HDC—Gilles de la Tourette syndrome	0.0001	0.000593	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	9.91e-05	0.000586	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	9.75e-05	0.000576	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	9.62e-05	0.000569	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	9.62e-05	0.000569	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	9.4e-05	0.000555	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	9.38e-05	0.000555	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	9.12e-05	0.000539	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—MET—Gilles de la Tourette syndrome	9.1e-05	0.000538	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	9.09e-05	0.000537	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	8.96e-05	0.00053	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	8.85e-05	0.000523	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	8.59e-05	0.000508	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	8.5e-05	0.000502	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	8.29e-05	0.00049	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	8.11e-05	0.000479	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	8e-05	0.000473	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	7.99e-05	0.000472	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	7.76e-05	0.000458	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	7.73e-05	0.000457	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	7.7e-05	0.000455	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	7.55e-05	0.000446	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	7.51e-05	0.000444	CbGpPWpGaD
Bosutinib—ABCB1—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	7.45e-05	0.000441	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	7.42e-05	0.000438	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	7.42e-05	0.000438	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	7.39e-05	0.000437	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	7.33e-05	0.000433	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	7.27e-05	0.00043	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	7.24e-05	0.000428	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	7.17e-05	0.000424	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	7.15e-05	0.000423	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	7.06e-05	0.000417	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	7.02e-05	0.000415	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	6.99e-05	0.000413	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	6.83e-05	0.000403	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	6.74e-05	0.000398	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	6.68e-05	0.000395	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	6.58e-05	0.000389	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	6.54e-05	0.000387	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	6.36e-05	0.000376	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	6.28e-05	0.000371	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	6.28e-05	0.000371	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—HDC—Gilles de la Tourette syndrome	6.18e-05	0.000365	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	6.1e-05	0.000361	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	6.06e-05	0.000358	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	5.95e-05	0.000352	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	5.88e-05	0.000347	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	5.68e-05	0.000336	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	5.61e-05	0.000331	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	5.48e-05	0.000324	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	5.36e-05	0.000317	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	5.21e-05	0.000308	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	4.9e-05	0.000289	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	4.85e-05	0.000287	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	4.78e-05	0.000283	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	4.68e-05	0.000277	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	4.61e-05	0.000272	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	4.58e-05	0.000271	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	3.98e-05	0.000235	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	3.84e-05	0.000227	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	3.4e-05	0.000201	CbGpPWpGaD
